Neurotez,Inc.
Neurotez, Inc. is a vibrant biotechnology company dedicated to developing innovative solutions for brain disorders, particularly Alzheimer's disease. Their mission is to become world leaders in biotechnology by utilizing an integrated platform from discovery to clinical trials for CNS drugs that are safe and effective. They focus on therapies involving Leptin, a hormone with potential to modify disease progression and improve cognition, and have a pipeline of products including Memtin, NT1, NT2, and screening platforms for molecular discovery.
Industries
Nr. of Employees
small (1-50)
Neurotez,Inc.
Patents
Methods for treating progressive cognitive disorders related to neurofibrillary tangles
US-8642543-B2
View Details
Methods for treating progressive cognitive disorders related to neurofibrillary tangles
US-8642543-B2
View DetailsProducts
Memtin (16 kDa biologic)
A 16 kDa biologic developed as a leptin-based therapeutic candidate for Alzheimer’s disease; in preclinical and clinical-readiness phases with planned progression to Phase 2 conditional on funding.
NT1 and NT2 (small peptide candidates)
Small peptides designed to disrupt a pathogenic presenilin–CLIP-170 interaction implicated in early-onset familial Alzheimer’s disease; candidates are at the end of discovery stage.
Screen A and Screen B (screening platforms)
Two discovery platforms: one to identify molecules at the intersection of metabolic and neurodegenerative pathways, and one to identify binding partners for specific protein targets.
Memtin (16 kDa biologic)
A 16 kDa biologic developed as a leptin-based therapeutic candidate for Alzheimer’s disease; in preclinical and clinical-readiness phases with planned progression to Phase 2 conditional on funding.
NT1 and NT2 (small peptide candidates)
Small peptides designed to disrupt a pathogenic presenilin–CLIP-170 interaction implicated in early-onset familial Alzheimer’s disease; candidates are at the end of discovery stage.
Screen A and Screen B (screening platforms)
Two discovery platforms: one to identify molecules at the intersection of metabolic and neurodegenerative pathways, and one to identify binding partners for specific protein targets.
Services
Discovery-stage screening, assay development, in vitro and in vivo testing, and preclinical candidate characterization for central nervous system drug candidates.
Discovery-stage screening, assay development, in vitro and in vivo testing, and preclinical candidate characterization for central nervous system drug candidates.
Expertise Areas
- Neurodegenerative disease drug development
- Biologic therapeutic development
- Preclinical model development and testing
- Assay and screening platform development
Key Technologies
- Biologic therapeutics (small proteins/peptides)
- Peptide-based inhibitors of protein–protein interactions
- High-throughput screening assays
- Cell-based molecular and biochemical assays